Get the app
USHealthcare

CeriBell, Inc (CBLL)

US · Healthcare · Medical Devices

$25.00+2.04%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$28.1M
Revenue YoY
+32.5%
Net profit
$-19.3M
EPS
$-0.51
EPS estimate
$-0.45
Net margin
-68.6%

EPS came in at -0.51 against a street estimate of -0.45 — a miss of 13.3%.

Key statistics

Market cap
$933.7M
Forward P/E
0.0
P/B
7.07
Book value
$3.36
EPS (TTM)
$-1.76
52-week high
$25.33
52-week low
$10.85
50-day MA
$21.10
200-day MA
$20.00

Analyst view

Analysts rate CeriBell, Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $28.00.

Shareholding

Insiders
11.91%
Institutions
87.73%

Largest institutional holders

FundStake
FMR Inc12.64%
TPG GP A, LLC10.34%
Red Tree Management, LLC5.75%
BlackRock Inc4.72%
Bank of New York Mellon Corp3.02%
Vanguard Capital Management, LLC2.96%
KCM Capital Inc2.93%
Federated Hermes Inc2.45%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
CERIBELL, INC. — QUARTERLY REPORT SUMMARY Q2 2026 (Period ended June 30, 2026) --- HEADLINE NUMBERS • Total Revenue (6 months): $54.6 million (up 3
2026-08-10
Results announced · Q3 2026
CERIBELL, INC. - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $28.1 million, up 33% from $21.2 million in Q2 2025 • Product re
2026-08-10
Board / officer change · Q3 2026
CERIBELL, INC. - 8-K SUMMARY (July 28, 2026) BUSINESS & SEGMENT HIGHLIGHTS • CeriBell, Inc. (ticker: CBLL) is a Nasdaq-listed medical device company
2026-07-30
Shareholder vote results · Q2 2026
CERIBELL, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 2, 2026 • Company trades on Nasdaq Global Select Market under t
2026-06-02
Quarterly report · Q1 2026
CERIBELL, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total revenue (Q1 2026): $26.5 million, up 29% from $20.5 million in Q1 2025 - Produ
2026-05-11
Results announced · Q2 2026
CERIBELL, INC. - Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $26.5 million — up 29% from $20.5 million in Q1 2025 •
2026-05-11
Proxy statement · Q2 2026
CERIBELL, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of two Class II directors—Josef Parvizi, M.D.,
2026-04-20
Annual report FY2025
CERIBELL, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: CeriBell, Inc. (Nasdaq: CBLL), Delaware incorporation, IRS ID 47-1785
2026-02-24

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CeriBell, Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.